• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $115.50 In stock
25 mg $173.30 In stock
100 mg $446.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S7970

    Strontium Ranelate

    Bone deterioration inhibitor, potential CaR ago...

    ≥98%
  • F4782

    Fludarabine Phosphate

    Nucleoside (adenosine) analog; DNA chain termin...

    ≥98%
  • I5357

    Inositol

    Endogenous sugar produced from glucose, require...

    ≥98%
  • B5728

    Bohemine

    Purine derivative; CDK inhibitor.

    ≥98%
  • P8382

    Puupehenone

    Sesquiterpene found in marine sponges.

    ≥94%
  • A4646

    ALLN

    Calpain I/II inhibitor.

    ≥98%
  • F3205

    Fibrinogen γ-chain Dodecapeptide

    Platelet substitute, peptide; GP IIb/IIIa activ...

    ≥95%
  • M0262

    Maprotiline Hydrochloride

    Tetracycline; FIASMA, histamine H1, 5-HT2, mACh...

    ≥98%
  • P6954

    Pioglitazone Hydrochloride

    Thiazolidinedione; PPARα/γ agonist, mitoNEET ...

    ≥98%
  • G1745

    Gemcitabine Hydrochloride

    Nucleoside (deoxycytidine) analog; ribonucleoti...

    ≥98%
  • P6004

    PP-242

    Dual mTORC1/mTORC2 inhibitor.

    ≥98%
  • A0902

    N-Acetyl-S-(N′-phenylhexylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant; HDAC inhib...

    ≥98%
  • N3378

    S-Nitrosoglutathione

    NO donor.

    ≥95%
  • D5746

    Dolasetron

    5-HT3 antagonist.

    ≥98%
  • P6802

    Pranoprofen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • N3496

    Nizatidine

    Histamine H2 inverse agonist.

    ≥98%
  • A4802

    Amantadine Hydrochloride

    Viral M2 proton channel blocker, MAO-A, NET, NM...

    ≥98%
  • F4400

    Flag Peptide

    Peptide, used to tag proteins for affinity chro...

    ≥95%
  • O451328

    Oligomycin C

    Macrocyclic lactone.

    ≥97%
  • R3014

    Recombinant TpN 47 protein

    Recombinant protein containing Treponema pallid...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only